USPTO issues Notify of Tolerance fitted Quick-Med Technologies’ NIMBUS technology
Quick-Med Technologies, Inc. (OTCBB:QMDT), a chairlady in developing innovative antimicrobial technologies after the healthcare and consumer markets, announced today that the U.S. Flagrant and Trademark Area has issued a Spot of Brooking towards sage worth that significantly adds to the tendency service mark coverage to go to the Company’s NIMBUS technology.
The Take of Consideration covers charter claims that give a speech to the bonding of the NIMBUS polymeric antimicrobial to a difference of form materials including woven and nonwoven fabrics. The cookie series of materials includes those that are composed of unpremeditated fibers, such as cotton and wool, as swell as synthetics such as polyurethane, polyester, nylon and polypropylene. The applications included in the allowed claims are because a congested spectrum of products such as medical devices including insult and throw dressings and blood conveyance and storage products, surgical drapes and rags, industrial and military possessive burden and consumer glad rags addition aseptic products such as wipes, diapers and sissified safe keeping.
"This Heed of Tolerance supplementary validates the innovative species of Quick-Med’s proprietary NIMBUS technology party line and underscores our company’s directorship in developing the primary non-leaching antimicrobial to hand in a shroud dressing," said J. Ladd Greeno, Quick-Med’s CEO. "We imagine that being the at best non-leaching antimicrobial dressing represents an high-level credit. Other antimicrobial dressings rely on the present of chemicals into the injury bed that can check the involved in healing process."
NIMBUS technology employs a riskless, eco-friendly effective instrument that remains in smack concentration on any of a handful substrates. It controls a non-specific area of both Gram-positive and Gram-negative bacteria. The NIMBUS antimicrobial is not depleted in handling, maintains effectiveness on a par in the self-assurance of great amounts of blood or richness fluids, and ;mainly map, poses no chance of bacteria developing irregulars.
NIMBUS non-leaching antimicrobial technology was cleared about FDA in 2009 and is readily obtainable in BIOGUARD™ impediment dressings from Derma Sciences and Medline, subsumed under a sneakily marker deal with Derma Sciences. Quick-Med is developing NIMBUS applications in certain other advanced stab dressing formats including adhesives, foams, hydrogels, films, and hydrocolloids.
A Discern of Allowing communicates the Apparent Office’s steadfastness that the applicant is entitled to a control under the law. The Players expects the remodelled unmistakable to be issued later this year.
PROVENANCE Quick-Med Technologies, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
